Søren Mouritsen

Genesto A/S develops and manufactures pharmaceutical products. It provides novel antibodies for the treatment of infectious diseases. The company was founded in November 2000 by Simon Rye Clausen and is headquartered in Hoersholm, Denmark.

PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease.

Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration

ROMO Wind AG provides products that focus on improving the wind turbine rotor function. It offers wind farm optimization, and yaw and pitch correction services. The firm also provides iSpin1, a retrofit product that is used for accurate detection and subsequent one-off correction of static or average wind turbine yaw misalignments. The company was founded by Soren Mouritsen, Poul Anker Lubker and Jan Nikolaisen in 2011 and is headquartered in Zug, Switzerland.

Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark.

Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023.